KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)

0.531
Delayed Data
As of May 28
 +0.009 / +1.72%
Today’s Change
0.36
Today|||52-Week Range
2.45
-69.31%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$17.2M

Company Description

KaloBios Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of monoclonal antibody therapeutics. It develops a portfolio of proprietary and patient-targeted monoclonal antibodies designed to treat severe life-threatening or debilitating diseases for which there is an unmet medical need, with a clinical focus on severe respiratory diseases and cancer. The company's antibody technology, Humaneered, treats serious medical conditions with a primary clinical focus on respiratory diseases and cancer. KaloBios Pharmaceuticals was founded on March 15, 2000 and is headquartered in South San Francisco, CA.

Contact Information

KaloBios Pharmaceuticals, Inc.
442 Littlefield Avenue
South San Francisco California 94080
P:(650) 243-3100
Investor Relations:

Employees

Shareholders

Other institutional9.59%
Individual stakeholders32.71%
Mutual fund holders15.15%

Top Executives

Herbert C. CrossChief Executive & Financial Officer
Geoffrey Thomas YarrantonChief Scientific Officer
Néstor A. MolfinoChief Medical Officer
Jeanne Y. JewSenior Vice President-Business Development
Harry LamSenior Vice President-Technical Operations

To view my watchlist

Not a member yet?

Sign up now for a free account